Почетна › Рак дојке › Merilend
Kliničke studije za Рак дојке u državi Merilend
65 studija za Рак дојке traži učesnike na lokacijama u državi Merilend.
Gradovi u državi Merilend
Zvanični tekst studije (na engleskom)
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникОпсервациона студија
Узраст од 18 до 120 · Оба пола · Ажурирано 13. 11. 2026. · NCT07619534Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Johns Hopkins Kimmel Cancer Center, Baltimore
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05696626A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Medstar Research Institute, Hyattsville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05894239Genomic Services Research Program
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникОпсервациона студија
1 Month – 105 Years · Оба пола · Ажурирано 12. 11. 2026. · NCT02595957S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- UM Upper Chesapeake Medical Center, Bel Air
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03418961Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 2
Узраст од 18 до 72 · Оба пола · Ажурирано 12. 11. 2026. · NCT01174121A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06966700Collection of Blood From Patients With Cancer
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT00034216Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT00451022The Vanguard Study: Testing a New Way to Screen for Cancer
- Walter Reed National Military Medical Center, Bethesda
Тражи се учесникЗдраве особе су добродошле
Узраст од 45 до 75 · Оба пола · Ажурирано 6. 11. 2026. · NCT06995898Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Baltimore
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- American Oncology Partners, PA, Bethesda
- James M Stockman Cancer Institute, Frederick
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Velocity Clinical Research, Annapolis
- University of Maryland, Baltimore
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- и још 14
Тражи се учесникФаза 3
Узраст од 18 до 50 · Оба пола · Ажурирано 4. 11. 2026. · NCT06748222Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- и још 10
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Christiana Care - Union Hospital, Elkton
- и још 3
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- United Theranostics, Glen Burnie
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07213791Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Mercy Medical Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
- и још 17
Тражи се учесникФаза 3
Узраст од 18 до 60 · Жене · Ажурирано 4. 11. 2026. · NCT05879926ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Saint Agnes Hospital, Clinical Research Center, Baltimore
- Maryland Oncology Hematology P.A., Columbia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07173751Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 2
Узраст од 18 до 72 · Оба пола · Ажурирано 30. 10. 2026. · NCT03412877Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 1/2
Узраст од 18 до 72 · Оба пола · Ажурирано 29. 10. 2026. · NCT02830724A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Maryland Oncology Hematology, Laurel
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT07102381EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Weinberg Center at Mercy, Baltimore
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- и још 7
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06401421Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- Sidney Kimmel Comprehensive Cancer Center, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT02422641A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
- Maryland Oncology Hematology, PA, Rockville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06172478A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Maryland Oncology Hematology - Annapolis, Annapolis
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT07100106The Cancer of the Pancreas Screening-5 CAPS5)Study
- Johns Hopkins Hospital, Baltimore
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT02000089A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Maryland Oncology Hematology P.A., Annapolis
- Mercy Medical Center - Baltimore, Baltimore
- Mfsmc-Hjwci, Baltimore
- и још 8
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07062965Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникОпсервациона студија
Узраст 3 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT01441089T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
- Maryland Oncology Hematology, P.A., Columbia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT07683754Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
- Walter Reed National Military Medical Center, Bethesda
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07140172A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Greenebaum Comprehensive Cancer Center ( Site 0036), Baltimore
- Holy Cross Hospital ( Site 0073), Silver Spring
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06312176A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Baltimore
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT05123482Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
- United Theranostics, Glen Burnie
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07311993Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- Maryland Proton Treatment Center, Baltimore
Тражи се учесникФаза 2
Узраст 50 и старији · Жене · Ажурирано 29. 9. 2026. · NCT01766297Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- Maryland Proton Treatment Center, Baltimore
Тражи се учесникФаза 3
Узраст 19 и старији · Жене · Ажурирано 29. 9. 2026. · NCT05856773A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Columbia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT06103864Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Annapolis
- Clinical Trial Site, Baltimore
- Clinical Trial Site, Baltimore
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT07085767Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT07340541Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.